Is Qiagen NV halal to invest in?

As of August 2026, Qiagen NV QGE2.VI is classified as halal according to Musaffa’s Shariah screening methodology. This classification is based on an assessment of the company’s business activities and financial ratios against Islamic investment guidelines.

Is Qiagen NV a Shariah-compliant stock?

A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Qiagen NV using these criteria to determine its compliance status.

Can Muslims buy shares of Qiagen NV?

Muslim investors may consider investing in Qiagen NV if it meets Shariah compliance standards. Investors typically review the company's business activities, debt levels, and non-permissible income before making a decision.

Why is Qiagen NV classified as HALAL?

Musaffa determines the Shariah status of Qiagen NV by analyzing whether the company's core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.

How often is the Shariah compliance for Qiagen NV updated?

The Shariah compliance status of Qiagen NV may be updated periodically when new financial statements, earnings reports, or business activity information become available.

Can a halal stock like Qiagen NV become non-compliant?

Yes. A stock that is currently Shariah-compliant may become non-compliant if the company's financial ratios exceed Shariah thresholds or its business activities change.

Where can I check the Shariah status of Qiagen NV?

You can check the latest Shariah compliance status of Qiagen NV on Musaffa's stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.

Qiagen NV QGE2.VI

Last Updated: Mar 13, 12:00 AM·WBAG

QGE2.VI Shariah Compliance

Screening Methodology: AAOIFI

As of August 2026, Qiagen NV is classified as halal.

HALAL

Report Source: undefined Quarter Report

Qiagen NV. Stock Analysis QGE2.VI

Austria Health Care Mid Cap

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company is headquartered in Venlo, Limburg and currently employs 5,765 full-time employees. The firm is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials. Its assay technologies make these biomolecules visible for analysis, such as identifying the genetic information of a pathogen or a gene mutation in a tumor. Its bioinformatics solutions interpret data to provide actionable insights. The firm's automation platforms based on polymerase chain reaction (PCR), next-generation sequencing (NGS) and other technologies tie these together in molecular testing workflows from Sample to Insight.